Cargando…

Clinical evidence on the efficacy and tolerability of a topical medical device containing benzoylperoxide 4%, retinol 0.5%, mandelic acid 1% and lactobionic acid 1% in the treatment of mild facial acne: an open label pilot study

Background: Acne is a debilitating disorder that requires proper treatment depending on the clinical manifestations and pathogenetic factors, among which hyper-keratinization, seborrhea and bacterial proliferation. Combining active ingredients targeting the different mediators of acne pathogenesis m...

Descripción completa

Detalles Bibliográficos
Autores principales: Garofalo, Virginia, Cannizzaro, Maria Vittoria, Mazzilli, Sara, Bianchi, Luca, Campione, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526677/
https://www.ncbi.nlm.nih.gov/pubmed/31190944
http://dx.doi.org/10.2147/CCID.S182317
_version_ 1783419937336852480
author Garofalo, Virginia
Cannizzaro, Maria Vittoria
Mazzilli, Sara
Bianchi, Luca
Campione, Elena
author_facet Garofalo, Virginia
Cannizzaro, Maria Vittoria
Mazzilli, Sara
Bianchi, Luca
Campione, Elena
author_sort Garofalo, Virginia
collection PubMed
description Background: Acne is a debilitating disorder that requires proper treatment depending on the clinical manifestations and pathogenetic factors, among which hyper-keratinization, seborrhea and bacterial proliferation. Combining active ingredients targeting the different mediators of acne pathogenesis may yield optimal outcomes. Purpose: The purpose of this study was to evaluate the clinical effectiveness, safety and tolerability of a new topical medical device in cream containing benzoylperoxide 4%, pure retinol 0.05%, palmitate retinol 0.5%, mandelic acid 1% and glycyrrhetic acid on patients with mild acne. Patients and methods: Twenty consecutive patients of both sexes with mild acne were included in the study. The topical treatment was self-applied twice a day for 12 weeks. Evaluations included: Global Acne Grading System (GAGS); inflammatory and non-inflammatory lesions count; reflectance confocal microscopy; seborrhea and hydration degree; photographic documentation; a questionnaire to assess tolerability. Results: The GAGS score showed a 39% reduction from T0 to T1 and 69.20% from T0 to T2. The count of comedonic lesions showed a 44% reduction from T0 to T1 and 65% from T0 to T2. The count of papular lesions diminished by 49.4% from T0 to T1 and by 62% from T0 to T2. The count of pustular lesions decreased by 43% from T0 to T1 and by 80% from T0 to T2. Improvement of hydration and a decrease of seborrhea degree were even observed. These clinical results were confirmed by reflectance confocal microscopy exam. Conclusion: The topical medical device has shown to be clinically effective and well tolerated for the treatment of mild acne. Side effects were mild, transient and well tolerated. The results of our study demonstrated a high tolerability of this new combination of benzoylperoxide 4% and retinol. Furthermore, our results suggested that the studied compound could be considered as a “maintenance treatment” after specific pharmacological treatment, even in more severe types of acne.
format Online
Article
Text
id pubmed-6526677
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65266772019-06-12 Clinical evidence on the efficacy and tolerability of a topical medical device containing benzoylperoxide 4%, retinol 0.5%, mandelic acid 1% and lactobionic acid 1% in the treatment of mild facial acne: an open label pilot study Garofalo, Virginia Cannizzaro, Maria Vittoria Mazzilli, Sara Bianchi, Luca Campione, Elena Clin Cosmet Investig Dermatol Original Research Background: Acne is a debilitating disorder that requires proper treatment depending on the clinical manifestations and pathogenetic factors, among which hyper-keratinization, seborrhea and bacterial proliferation. Combining active ingredients targeting the different mediators of acne pathogenesis may yield optimal outcomes. Purpose: The purpose of this study was to evaluate the clinical effectiveness, safety and tolerability of a new topical medical device in cream containing benzoylperoxide 4%, pure retinol 0.05%, palmitate retinol 0.5%, mandelic acid 1% and glycyrrhetic acid on patients with mild acne. Patients and methods: Twenty consecutive patients of both sexes with mild acne were included in the study. The topical treatment was self-applied twice a day for 12 weeks. Evaluations included: Global Acne Grading System (GAGS); inflammatory and non-inflammatory lesions count; reflectance confocal microscopy; seborrhea and hydration degree; photographic documentation; a questionnaire to assess tolerability. Results: The GAGS score showed a 39% reduction from T0 to T1 and 69.20% from T0 to T2. The count of comedonic lesions showed a 44% reduction from T0 to T1 and 65% from T0 to T2. The count of papular lesions diminished by 49.4% from T0 to T1 and by 62% from T0 to T2. The count of pustular lesions decreased by 43% from T0 to T1 and by 80% from T0 to T2. Improvement of hydration and a decrease of seborrhea degree were even observed. These clinical results were confirmed by reflectance confocal microscopy exam. Conclusion: The topical medical device has shown to be clinically effective and well tolerated for the treatment of mild acne. Side effects were mild, transient and well tolerated. The results of our study demonstrated a high tolerability of this new combination of benzoylperoxide 4% and retinol. Furthermore, our results suggested that the studied compound could be considered as a “maintenance treatment” after specific pharmacological treatment, even in more severe types of acne. Dove 2019-05-15 /pmc/articles/PMC6526677/ /pubmed/31190944 http://dx.doi.org/10.2147/CCID.S182317 Text en © 2019 Garofalo et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Garofalo, Virginia
Cannizzaro, Maria Vittoria
Mazzilli, Sara
Bianchi, Luca
Campione, Elena
Clinical evidence on the efficacy and tolerability of a topical medical device containing benzoylperoxide 4%, retinol 0.5%, mandelic acid 1% and lactobionic acid 1% in the treatment of mild facial acne: an open label pilot study
title Clinical evidence on the efficacy and tolerability of a topical medical device containing benzoylperoxide 4%, retinol 0.5%, mandelic acid 1% and lactobionic acid 1% in the treatment of mild facial acne: an open label pilot study
title_full Clinical evidence on the efficacy and tolerability of a topical medical device containing benzoylperoxide 4%, retinol 0.5%, mandelic acid 1% and lactobionic acid 1% in the treatment of mild facial acne: an open label pilot study
title_fullStr Clinical evidence on the efficacy and tolerability of a topical medical device containing benzoylperoxide 4%, retinol 0.5%, mandelic acid 1% and lactobionic acid 1% in the treatment of mild facial acne: an open label pilot study
title_full_unstemmed Clinical evidence on the efficacy and tolerability of a topical medical device containing benzoylperoxide 4%, retinol 0.5%, mandelic acid 1% and lactobionic acid 1% in the treatment of mild facial acne: an open label pilot study
title_short Clinical evidence on the efficacy and tolerability of a topical medical device containing benzoylperoxide 4%, retinol 0.5%, mandelic acid 1% and lactobionic acid 1% in the treatment of mild facial acne: an open label pilot study
title_sort clinical evidence on the efficacy and tolerability of a topical medical device containing benzoylperoxide 4%, retinol 0.5%, mandelic acid 1% and lactobionic acid 1% in the treatment of mild facial acne: an open label pilot study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526677/
https://www.ncbi.nlm.nih.gov/pubmed/31190944
http://dx.doi.org/10.2147/CCID.S182317
work_keys_str_mv AT garofalovirginia clinicalevidenceontheefficacyandtolerabilityofatopicalmedicaldevicecontainingbenzoylperoxide4retinol05mandelicacid1andlactobionicacid1inthetreatmentofmildfacialacneanopenlabelpilotstudy
AT cannizzaromariavittoria clinicalevidenceontheefficacyandtolerabilityofatopicalmedicaldevicecontainingbenzoylperoxide4retinol05mandelicacid1andlactobionicacid1inthetreatmentofmildfacialacneanopenlabelpilotstudy
AT mazzillisara clinicalevidenceontheefficacyandtolerabilityofatopicalmedicaldevicecontainingbenzoylperoxide4retinol05mandelicacid1andlactobionicacid1inthetreatmentofmildfacialacneanopenlabelpilotstudy
AT bianchiluca clinicalevidenceontheefficacyandtolerabilityofatopicalmedicaldevicecontainingbenzoylperoxide4retinol05mandelicacid1andlactobionicacid1inthetreatmentofmildfacialacneanopenlabelpilotstudy
AT campioneelena clinicalevidenceontheefficacyandtolerabilityofatopicalmedicaldevicecontainingbenzoylperoxide4retinol05mandelicacid1andlactobionicacid1inthetreatmentofmildfacialacneanopenlabelpilotstudy